- Dosage: Sulfadoxine/Pyrimethamine 175 mg and Amodiaquine 75mg
- Packaging: 9 tablets/blister*10/box
- Shelf Life: 36months
Package:
Product Description
Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg: What the Published Guidance Says
Artemisinin-based combination therapy is the WHO-recommended backbone of falciparum malaria treatment.
Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg is specified against its own monograph, pack size and market registration, so the guidance below is worth reading together with the Malaria & ACTs range overview.
- The ACT combinations and their strengths are specified on the WHO Model List Section 6.5.3.1 of the 24th WHO Model List (2025) specifies the curative antimalarials, including artemether + lumefantrine tablet 20 mg + 120 mg and a dispersible tablet, artesunate + amodiaquine, artesunate + mefloquine, artesunate + pyronaridine as granules and tablets, dihydroartemisinin + piperaquine across four tablet strengths, and artesunate co-packaged with sulfadoxine + pyrimethamine. WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)
- One combination to handle with care MSF notes that the artesunate + sulfadoxine/pyrimethamine combination is contraindicated in HIV-infected women taking co-trimoxazole preventive therapy, and that artesunate/mefloquine should not be used where neurological signs developed during the acute phase. MSF Medical Guidelines — Malaria (Chapter 4.3, Parasitic infections)
- ACT is the treatment of choice in all trimesters For uncomplicated P. falciparum malaria, MSF medical guidelines state the treatment of choice in all trimesters is an artemisinin-based combination therapy taken for three days. Co-formulated and co-blistered regimens are both described, including artemether/lumefantrine 20/120 mg and 80/480 mg, artesunate/amodiaquine, artesunate/mefloquine and dihydroartemisinin/piperaquine. MSF Medical Guidelines — Malaria (Chapter 4.3, Parasitic infections)
We quote these sources rather than paraphrase them loosely, because the detail matters commercially for Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg. Where your national list differs from the WHO listing, the national list governs what may be supplied and promoted locally.
Supply & Specification Data for Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg
| Product Name | Sulfadoxine/Pyrimethamine + Amodiaquine Tablets (Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg Oral Tablets) |
| Specification | Each tablet contains: Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg |
| Dosage Form | Oral Film-Coated Tablet (for oral administration) |
| Active Ingredients | Sulfadoxine / Pyrimethamine / Amodiaquine |
| Pharmacological Class | Antimalarial Combination (Sulfonamide / Antifolate / 4-Aminoquinoline) |
| Route of Administration | Oral administration (swallowed whole with water; take with food to reduce gastrointestinal upset). Take at approximately the same time each day during the treatment course. |
| Storage | Store below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze. |
| Therapeutic group | Malaria & ACTs — Malaria & ACTs |
| Manufacturer | Sinophare Bio-technology Co., Ltd. (GMP, China) |
| Documentation supplied | COA, HPLC/GC data, stability data, dossier package |
The same therapeutic range is supplied in several presentations, so one purchase order can cover a mixed requirement: Chloroquine Phosphate 500mg Tablets, Dihydroartemisinin 40mg + Piperaquine 320mg Tablets, Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg, Artesunate 200mg + Amodiaquine 600mg Tablets, Artesunate 400mg Mefloquine 500mg Tablets, Artemether Lumefantrine 80/480mg Tablets, Artesunate Suppositories 100mg, Artemether 80mg Injection.
Testing, Monographs & Batch Documentation
Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.
Every batch of Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg is tested to the monograph stated on the purchase order. Where a monograph is silent on the presentation, we agree a written specification with you in advance and reference it on the certificate of analysis.
Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.
The batch record for this product normally includes:
- Testing for water content and pH where applicable
- Testing for sterility and bacterial endotoxins (parenterals and ophthalmics)
- Testing for microbial limits and preservative efficacy (multi-dose presentations)
- Testing for heavy metals and elemental impurities
- Testing for packaging integrity and seal testing
- Testing for description and identification
COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.
Pack Configuration, Artwork & Shipping Documents
- Pack size: Blister pack (PVC-Alu) or strip pack, typically per treatment course. Non-standard pack sizes can be quoted against your artwork.
- Storage: Store below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze..
- Shelf life: 36 months (unopened). Stability data for the marketed pack is included in the dossier.
- Labelling: we typeset the carton and leaflet in English, Arabic, French, Russian and Spanish and in any further language your market requires, carrying your own brand where the local rules allow.
- Export: commercial invoice, packing list, certificate of origin, GMP certificate, COA and the free-sale certificate issued by the country of manufacture whenever your customs or regulator asks for it.
Dossier, Authority Filings & Tender Documentation
Documents for Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg are issued by Sinophare Bio-technology Co., Ltd. — DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. Keeping one legal manufacturer across the COA, the GMP certificate and the registration file avoids assessment queries later.
- Artwork and mock-up approval pack, showing the carton, label and leaflet exactly as they will be printed for your market.
- Batch manufacturing and packaging records released for inspection on request during supplier audits.
- Re-test or renewal support when the marketing authorisation comes up for variation or renewal.
- CTD dossier modules 1–5 in editable and PDF form, with the finished-product and API sections cross-referenced.
- Site Master File and GMP certificate for the manufacturing workshops.
The context for Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg is its place among ACT regimens named in the WHO Model List of Essential Medicines. Listing status informs how programmes specify a product; it is not a substitute for the import licence or marketing authorisation of the destination country.
Buyer Questions about Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg
What pack size is available for Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg?
This presentation is normally supplied as Blister pack (PVC-Alu) or strip pack, typically per treatment course. Where your market requires a different count, bottle or carton, we quote to your artwork and extend the stability file to the new pack.
What documentation comes with a shipment of Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg?
Shipments are accompanied by a certificate of analysis covering identification, assay and related substances, together with the marketed-pack stability data and the manufacturing site GMP certificate. Shelf life: 36 months.
Does the batch documentation for Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg support a registration filing?
Shipments are accompanied by a certificate of analysis covering identification, assay and related substances, together with the marketed-pack stability data and the manufacturing site GMP certificate. Shelf life: 36 months. The full CTD dossier and the authority assessment file are supplied as part of a registration order; routine shipments carry the COA and stability data only.
Which ACT combinations appear on the WHO Model List?
The 24th List (2025) specifies artemether + lumefantrine, artesunate + amodiaquine, artesunate + mefloquine, artesunate + pyronaridine, dihydroartemisinin + piperaquine, artesunate co-packaged with sulfadoxine + pyrimethamine, and chloroquine restricted to P. vivax.
Do you supply dispersible paediatric ACTs?
Yes. We supply dispersible and dry-suspension presentations aligned to the strengths in the Model List, including artemether + lumefantrine 20/120 mg dispersible tablets and paediatric suspensions.
Other Malaria & ACTs Products in This Range
- Chloroquine Phosphate 500mg Tablets — 500mg
- Dihydroartemisinin 40mg + Piperaquine 320mg Tablets — 40mg
- Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg — 175mg
- Artesunate 200mg + Amodiaquine 600mg Tablets — 200mg
- Artesunate 400mg Mefloquine 500mg Tablets — 400mg
- Artemether Lumefantrine 80/480mg Tablets — 80mg
Browse the full Malaria & ACTs range; all Tablets; the complete product catalogue.
Request a Quotation for Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg
For tenders and programme supply, send the line item, pack size, quantity and destination for Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg 175mg. We return a quotation with lead time, documentation list and sample availability in one response.
Sources & Regulatory Notes
- WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)
- MSF Medical Guidelines — Malaria (Chapter 4.3, Parasitic infections)
Reference information only. The published guidance summarised on this page is quoted for professional and regulatory-context purposes and does not constitute medical advice, a prescribing recommendation or a promotion of any product for a particular indication. Prescribing decisions must follow the approved product information and national treatment guidelines in the market of use.
